(Q36687060)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Treatment of psychosis: 30 years of progress (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Mario F. Juruena

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

I R De Oliveira

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

523-534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17176358%20AND%20SRC:MED&resulttype=core&format=json

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Use of magnetic resonance imaging in tracking the course and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

What's atypical about atypical antipsychotic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

The safety and tolerability of atypical antipsychotics in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Ziprasidone: a novel psychotropic with unique properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Aripiprazole: pharmacology, efficacy, safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

21 January 2018

The history of clozapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Letter: Clozapine and agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Leponex--associated granulocytopenia: a review of the situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X

Use of aripiprazole for psychosis and agitation in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00784.X